PURPOSE: Pegylated interferon (Peg-IFN)-based therapy is effective in treating chronic hepatitis B (CHB) and C (CHC) but frequently induces adverse events (AEs). This study was conducted to compare the incidence of Peg-IFN-based therapy-associated AEs in Taiwanese patients with CHB and CHC. METHODS: Fifty-six patients with CHB and 103 age-, sex- and treatment duration-matched patients with CHC were enrolled. Patients with CHB were treated with Peg-IFN-α-2a 180 μg/week for 24 weeks (HBeAg(+), n = 31) or 48 weeks (HBeAg(-), n = 25); patients with CHC were treated with Peg-IFN-α-2a 180 μg/week plus ribavirin 1,000-1,200 mg/day for 24 weeks (genotype 2/3, n = 57) or 48 weeks (genotype 1, n = 46). RESULTS: Significantly higher incidences of Peg-IFN-related AEs, especially neuropsychiatric symptoms, and ribavirin-associated skin manifestations were observed in patients with CHC compared with those with CHB, with either the 24- or 48-week regimen. Frequencies of laboratory abnormalities, except for anemia, were comparable in both groups. Neither group showed overt hepatic decompensation. Frequency of dose reduction was similar between the groups. Substantially higher rates of early termination and severe AEs were observed in patients with CHC. CONCLUSIONS: Patients with CHB treated with Peg-IFN had fewer AEs than patients with CHC treated with Peg-IFN/ribavirin. All patients were treated safely.
PURPOSE: Pegylated interferon (Peg-IFN)-based therapy is effective in treating chronic hepatitis B (CHB) and C (CHC) but frequently induces adverse events (AEs). This study was conducted to compare the incidence of Peg-IFN-based therapy-associated AEs in Taiwanese patients with CHB and CHC. METHODS: Fifty-six patients with CHB and 103 age-, sex- and treatment duration-matched patients with CHC were enrolled. Patients with CHB were treated with Peg-IFN-α-2a 180 μg/week for 24 weeks (HBeAg(+), n = 31) or 48 weeks (HBeAg(-), n = 25); patients with CHC were treated with Peg-IFN-α-2a 180 μg/week plus ribavirin 1,000-1,200 mg/day for 24 weeks (genotype 2/3, n = 57) or 48 weeks (genotype 1, n = 46). RESULTS: Significantly higher incidences of Peg-IFN-related AEs, especially neuropsychiatric symptoms, and ribavirin-associated skin manifestations were observed in patients with CHC compared with those with CHB, with either the 24- or 48-week regimen. Frequencies of laboratory abnormalities, except for anemia, were comparable in both groups. Neither group showed overt hepatic decompensation. Frequency of dose reduction was similar between the groups. Substantially higher rates of early termination and severe AEs were observed in patients with CHC. CONCLUSIONS:Patients with CHB treated with Peg-IFN had fewer AEs than patients with CHC treated with Peg-IFN/ribavirin. All patients were treated safely.
Authors: S Zeuzem; S V Feinman; J Rasenack; E J Heathcote; M Y Lai; E Gane; J O'Grady; J Reichen; M Diago; A Lin; J Hoffman; M J Brunda Journal: N Engl J Med Date: 2000-12-07 Impact factor: 91.245
Authors: K L Lindsay; C Trepo; T Heintges; M L Shiffman; S C Gordon; J C Hoefs; E R Schiff; Z D Goodman; M Laughlin; R Yao; J K Albrecht Journal: Hepatology Date: 2001-08 Impact factor: 17.425
Authors: H L Janssen; G Gerken; V Carreño; P Marcellin; N V Naoumov; A Craxi; H Ring-Larsen; G Kitis; J van Hattum; R A de Vries; P P Michielsen; F J ten Kate; W C Hop; R A Heijtink; P Honkoop; S W Schalm Journal: Hepatology Date: 1999-07 Impact factor: 17.425
Authors: Vijayan Balan; David Schwartz; George Y Wu; Andrew J Muir; Reem Ghalib; John Jackson; Emmet B Keeffe; Lorenzo Rossaro; Alfreda Burnett; Betty L Goon; Peter J Bowers; Gerhard J Leitz Journal: Am J Gastroenterol Date: 2005-02 Impact factor: 10.864
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: K R Reddy; T L Wright; P J Pockros; M Shiffman; G Everson; R Reindollar; M W Fried; P P Purdum; D Jensen; C Smith; W M Lee; T D Boyer; A Lin; S Pedder; J DePamphilis Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: Karin Weissenborn; Jochen Krause; Martin Bokemeyer; Hartmut Hecker; Andreas Schüler; Jochen C Ennen; Björn Ahl; Michael P Manns; Klaus W Böker Journal: J Hepatol Date: 2004-11 Impact factor: 25.083
Authors: Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu Journal: N Engl J Med Date: 2002-09-26 Impact factor: 91.245
Authors: W G E Cooksley; T Piratvisuth; S-D Lee; V Mahachai; Y-C Chao; T Tanwandee; A Chutaputti; W Yu Chang; F E Zahm; N Pluck Journal: J Viral Hepat Date: 2003-07 Impact factor: 3.728
Authors: Thalia Medeiros; Camila de Morais Salviato; Natalia Fonseca do Rosário; Geórgia do Nascimento Saraiva; Eliane Bordalo Cathalá Esberard; Jorge Reis Almeida; Analúcia Rampazzo Xavier; Andrea Alice da Silva Journal: Int J Clin Pharm Date: 2017-10-27